BMJ4d
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Correspondence to Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden D-01307, Germany; martin.aringer{at}uniklinikum-dresden.de; Dr ...
BMJ1d
POS0146 PERIPHERAL NEUROPATHY IN PSORIASIS AND PSORIATIC ARTHRITIS: A SINGLE BLIND, CONTROLLED, ELECTROPHYSIOLOGICAL STUDY
1 Prof Dr Cemil Tascioglu City Hospital, Physical Medicine and Rehabilitation Clinic, Ä°stanbul, Turkey 2 Prof Dr Cemil Tascioglu City Hospital, Neurology Clinic, Ä°stanbul, Turkey 3 Prof Dr Cemil ...
BMJ6d
Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis
Objectives The International League of Associations for Rheumatology classification criteria define systemic juvenile idiopathic arthritis (SJIA) by the presence of fever, rash and chronic arthritis.
BMJ6d
Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis
Correspondence to Dr Ki-Jo Kim, Division of Rheumatology, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, 93, Jungbu-daero, Paldal-gu, ...
BMJ5d
Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
Objective To investigate the association between baseline disease activity and the occurrence of flares after adalimumab tapering or withdrawal in patients with rheumatoid arthritis (RA) in sustained ...
BMJ4d
Mechanical overloading promotes chondrocyte senescence and osteoarthritis development through downregulating FBXW7
Objectives To investigate the role of mechanical stress in cartilage ageing and identify the mechanistic association during osteoarthritis (OA) progression. Conclusions FBXW7 is a key factor in the ...
BMJ4d
Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017
Objectives To report the level and trends of prevalence, incidence and years lived with disability (YLDs) for osteoarthritis (OA) in 195 countries and territories from 1990 to 2017 by age, sex and ...
BMJ7d
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
Background The best strategy for maintaining clinical remission in patients with axial spondyloarthritis (axSpA) has not been defined. C-OPTIMISE compared dose continuation, reduction and withdrawal ...
BMJ10d
Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial
1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...
BMJ5d
Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse
1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...
BMJ6d
Mortality and causes of death in a Swedish series of systemic sclerosis patients
OBJECTIVES To analyse survival rates and the causes of death in a systemic sclerosis (SSc) population, and to evaluate the occurrence of fatal malignant neoplasms and their possible association with ...
BMJ7d
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
Objective To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). Methods This phase III, randomised, double-blind, placebo-controlled study enrolled ...